Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 4263017, 10 pages
Research Article

Treatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF Agents: Predictive Factors of Long-Term Visual Outcomes

1Department of Ophthalmology, Centro Hospitalar São João, Porto, Portugal
2Department of Sense Organs, Faculty of Medicine of the University of Porto, Porto, Portugal
3Department of Anatomy, Faculty of Medicine of the University of Porto, Porto, Portugal

Correspondence should be addressed to Ana Catarina Pedrosa; moc.liamg@asordep.c.aniratac

Received 6 December 2016; Revised 7 March 2017; Accepted 19 March 2017; Published 1 June 2017

Academic Editor: Siamak Ansari-Shahrezaei

Copyright © 2017 Ana Catarina Pedrosa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To evaluate the predictive factors of long-term visual outcomes in neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (anti-VEGF) agents. Methods. Unicentric retrospective review of patients with nAMD treated with anti-VEGF agents. Visual outcomes, 12 and 60 months after diagnosis, were evaluated. In an attempt to identify predictive factors of visual outcomes, multiple variables (demographic and epidemiological characteristics, angiographic and tomographic features) were analyzed, at baseline and during follow-up. Results. One hundred and seventeen patients were included. In multivariate analysis, baseline best-corrected visual acuity was associated with all visual endpoints at 12 and 60 months. Additionally, age, gender, number of injections, and development of subretinal fibrosis during follow-up were also significant predictors of visual outcomes at 60 months. Conclusions. Several factors can be useful in clinical practice as predictors of visual outcomes in response to anti-VEGF treatment of nAMD.